OSAAI 2017 Northwest Allergy Forum

Portland, OR US
October 13, 2017 to October 15, 2017

Didactic lectures allowing the speakers to provide evidence based medical recommendations, updates and expert opinion in an efficient manner.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma and Immunology (ACAAI) and the Oregon Society of Allergy, Asthma and Immunology (OSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma and Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding
There is no commercial support for this activity.

Target Audience

Practicing allergists and allied healthproviders in the field of allergy, asthma and immunology.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1.  Improve recognition of autoinflammtory disease and the underlying pathophysiology
  2.  Direct approbation testing and treatment for autoimflammatory disease
  3.  Implement cost effective genetic testing for patients with atopic and immunologic disease
  4.  Apply the appropriate treatment for nonallergic disease based on symptomatic needs of the patient
  5.  Identify the differential diagnosis of atopic dermatitis
  6.  Manage emerging treatments for recalcitrant atopic dermatitis
  7.  Differentiate between asthma, COPD and asthma/COPD overlap and prescribe appropriate treatment
  8.  Improved recognition of obstructive sleep apnea and direct appropriate referrals for testing/treatment
  9.  Recognize the symptoms of cystic fibrosis to allow expedited testing and treatment
Additional information
Disclosure: 

Disclosure Policy and Disclosures:

As required by the Accreditation Council for Continuing Medical Education (ACCME)  in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Gopal Allada, MD Speaker

Consultant: Vertex Pharmaceuticals

Mark Boguniewicz, MD Speaker

Speaker/Consultant: Regeneron

Advisory Board/Speaker: Sanofi

Hal Hoffman, MD Speaker

Consulting/Speaker: Novartis

John Oppenheimer, MD Speaker

Adjudication Committee: AstraZeneca/TEVA

Consultant/Advisory Board: DBV

Advisory Board: GSK

Author:Medscopre/UpToDate/Annals of Int Med

Jonathan Bernstien, MD Speaker

Consultant: AstraZeneca/ Boehringer Ingelheim/ CSL Behring/Shire/Novartis/Sanofi

Independent Contractor: Boehringer Ingelheim/CSL Behring/Shire/Novartis

Speaker CSL Behring/Shire/Novartis/Sanofi

Advisory Board: AstraZeneca/CSL Behring/Shire/Novartis

Independent Contractor: Sanofi

Guha Krishnaswamy,MD Speaker

 Research Grant: CSL Behring

UpToDate: Author

The following have no relevant financial relationship to disclose:

Justin Treat, DO Moderator

Adam Williams, MD Planner            

Raj Srinivasan, MD Planner

Sarah Kehl, MD Moderator

Alice Chou, MD Planner

Alison Dodenhoff, Meeting Coordinator

Education Staff have no relevant financial relationship to disclose, except as may be listed above.

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Course opens: 
10/13/2017
Course expires: 
10/15/2019
Event starts: 
10/13/2017 - 5:00pm CDT
Event ends: 
10/15/2017 - 11:45am CDT
Add to calendar: 
Rating: 
0
Portland Marriott Downtown Waterfront
1401 SW Naito Parkway
Portland, OR 97201
United States
+1 (503) 226-7600

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma and Immunology (ACAAI) and the Oregon Society of Allergy, Asthma and Immunology (OSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma and Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Please login or create an account to take this course.